IMS Health Forecasts Continued Double-Digit Annual Growth of Cancer Therapeutics
New products and combination therapies. IMS expects future growth to be bolstered by the introduction of 25 to 30 new chemical entities between 2008 and 2012, helping to sustain the trend of an expanding patient population treated with targeted therapies. While many of these new therapies will treat the most prevalent tumor types — breast and non-small cell lung cancer — several new drugs in late-stage development will target prostate and pancreatic cancer as well as melanoma.
This entry was posted on Friday, May 16th, 2008 at 11:39 am and is filed under Research, Non-Small-Cell. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.